Last reviewed · How we verify
JMKX003948
At a glance
| Generic name | JMKX003948 |
|---|---|
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of JMKX003948 Ophthalmic Suspension in Healthy Participants (PHASE1)
- A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX003948 CI brief — competitive landscape report
- JMKX003948 updates RSS · CI watch RSS
- Jemincare portfolio CI